Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C

Liver International

Volumn 28, Issue 8, 2008, Pages 1112-1119

  Gad, Rita Raafat ^a   Males, Sylvia ^b   El Makhzangy, Hesham ^c   Shouman, Soheir ^d   Hasan, Aboubakr ^d   Attala, Mohamed ^d   El Hoseiny, Mostafa ^a   Zalata, Khaled ^e   Abdel Hamid, Mohamed ^f,g   Fontanet, Arnaud ^b   Mohamed, Mostafa K ^a   Esmat, Gamal ^c  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b INSTITUT PASTEUR   (France)

^c CAIRO UNIVERSITY   (Egypt)

^d Research Institute ^*  (Egypt)

^e MANSOURA UNIVERSITY   (Egypt)

^f NATIONAL HEPATOLOGY AND TROPICAL MEDICINE RESEARCH INSTITUTE   (Egypt)

^g Minia University   (Egypt)

Author keywords

fetoprotein; Adherence to treatment; Chronic hepatitis C; Pegylated interferon; Sustained virological response; Treatment response predictors

Indexed keywords

ALPHA FETOPROTEIN; INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; EGYPT; FATTY LIVER; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PATIENT COMPLIANCE; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTEIN BLOOD LEVEL; VIRUS DETECTION;

ADULT; ALPHA-FETOPROTEINS; ANTIVIRAL AGENTS; FATTY LIVER; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 48949094213     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01750.x     Document Type: Article

References (31)

1. World Health Organization. Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6: 35-47.
2. Ray SC, Arthur RR, Carella A, et al. Genetic epidemiology of hepatitis C virus throughout Egypt. J Infect Dis 2000; 182: 698-707.
3. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358: 958-65.
4. Kamal SM, El Tawil AA, Nakano T, et al. Peginterferon alpha-2b and ribavirin therapy in chronic hepatitis C genotype 4 impact of treatment duration and viral kinetics on sustained virological response. Gut 2005; 54: 858-66.
5. Males S, Gad, Esmat G, et al. Serum alpha-fetoprotein (AFP) level predicts treatment outcome in chronic hepatitis C. Antivir Ther 2007; 12: 797-803.
6. Hu KQ, Vierling JM, Redeker AG. Viral, host and interferon related factors modulating the effect of interferon therapy for hepatitis C virus infection. J Viral Hepat 2001; 8: 1-18.
7. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for non response to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38: 557-9.
8. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: Who responds less well? Ann Intern Med 2004; 140: 370-81.
9. Berg T, Sarrazin C, Hermann E, et al. Prediction of treatment outcome in patients with chronic hepatitis C: Significance of baseline parameters and viral dynamics during therapy. Hepatology 2003; 37: 600-9.
10. Brau N, Bini EJ, Currie S, et al. Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin. J Viral Hepat 2006; 13: 242-9.
11. Hasan F, Al-Khaldi J, Asker H, et al. Peginterferon alpha-2b plus ribavirin with or without amantadine [correction of amantidine] for the treatment of non-responders to standard interferon and ribavirin. Antivir Ther 2004; 9: 499-503.
12. Roulot D, Bourcier V, Grando V, et al. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat 2007; 14: 460-7.
13. Kamal SM, El Kamary SS, Shardell MD, et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: the role of rapid and early virologic response. Hepatology 2007; 46: 1732-40.
14. Simmonds P, Holmes EC, Cha TA, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993; 74: 2391-9.
15. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-93.
16. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-74.
17. McHutchison JG, Manns M, Patel K, et al. for the International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in genotype-1 infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-9.
18. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358: 958-65.
19. Parise ER, de Oliveira AC, Conceicao RDO, Amaral AC. Response to treatment with interferon alpha and ribavirin in patients with chronic hepatitis C virus genotypes 2 and 3 depends on the degree of hepatic fibrosis. Braz J Infectious Dis 2006; 10: 78-81.
20. Meyers RP, Patel K, Pianko S, Poynard T, McHutchison JG. The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C. J Viral Hepat 2003; 10: 16-22.
21. Akuta N, Suzuki F, Sezaki H, et al. Predictive factors of virologic-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol 2006; 78: 83-90.
22. Negro F. Mechanisms and significance of liver steatosis in hepatitis C virus infection. World J Gastroenterol 2006; 12: 6756-65.
23. Dev A, Patel K, McHutchison JG. Hepatitis C and steatosis. Clin Liver Dis 2004; 8: 881-92.
24. Patton HM, Patel K, Behling C, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004; 40: 484-90.
25. Germain L, Noel M, Gourdeau H, Marceau N. Promotion of growth and differentiation of rat ductular oval cells in primary culture. Cancer Res 1988; 48: 368-78.
26. Shiojiri N, Lemire JM, Fausto N. Cell lineages and oval cell progenitors in rat liver development. Cancer Res 1991; 51: 2611-20.
27. Dabeva MD, Shafritz DA. Activation, proliferation, and differentiation of progenitor cells into hepatocytes in the d-galactosamine model of liver regeneration. Am J Pathol 1993; 143: 1606-20.
28. Tsamandas AC, Syrokosta I, Thomopoulos K, et al. Potential role of hepatic progenitor cells expression in cases of chronic hepatitis C and their relation to response to therapy: A clinicopathologic study. Liver Int 2006; 26: 817-26.
29. Bruno R, Sacchi P, Maiocchi L, Zocchetti C, Filice G. Host factors affecting the outcome of treatment of hepatitis C. Rev Gastroenterol Disord 2004; 4 (Suppl. 1): S3-7.
30. Bhattacherjee V, Prescott LE, Pike I, et al. Use of NS-4 peptides to identify type-specific antibody to hepatitis C virus genotypes 1, 2, 3, 4, 5 and 6. J Gen Virol 1995; 76: 1737-48.
31. Chamberlain RW, Adams N, Saeed AA, Simmonds P, Elliott RM. Complete nucleotide sequence of a type 4 hepatitis C virus variant, the predominant genotype in the Middle East. J Gen Virol 1997; 78: 1341-7.